Ownership history in Medicxi Ventures Management (Jersey) Ltd Β· 13 quarters on record
This page tracks every 13F SEC filing in which Medicxi Ventures Management (Jersey) Ltd reported a position in NEWAMSTERDAM PHARMA COMPANY (NAMS). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price β sourced directly from SEC EDGAR 13F filings.
π Medicxi Ventures Management (Jersey) Ltd outperformed the S&P 500 by +41.3% annually on this NAMS position. Average cost basis: $11.89. Maximum drawdown during holding period: β30.2%.
π₯ Exceptional β beat the S&P 500 by 41.3% per year on this position.
11 quarters analyzed
Best entry: $11.89 (2023 Q2) Β· Worst: $11.89 (2023 Q2)
πͺ Held through 3 major drawdowns (>20%). Diamond-hands conviction.
2 adds Β· 0 trims. Bought during 1 of 6 down-price quarters. π Consistently bullish β fund kept accumulating this position.
π Portfolio weight has been declining in recent quarters. Possible distribution phase.
Currently 12.06% of portfolio
β Based on quarterly 13F SEC filings and end-of-quarter closing prices. Timing score = accuracy of add/trim decisions vs next-quarter price direction. Alpha = mean quarterly excess return Γ 4 (annualised). Not investment advice.
As of 2025 Q4 β sorted by position size